Evidence map›Paper›PMID 32510984›Full record

Trial reportCirculation. Genomic and precision medicine2020

Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.

Chengxian Guo, Yun Kuang, Honghao Zhou, Hong Yuan, Qi Pei, Jingle Li, Weihong Jiang, Chee M Ng, Xiaoping Chen, Yong Huo and 44 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Genomic and precision medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02211326 (Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02211326 nacompletednot on this map

Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients

TypeinterventionalSponsorThe Third Xiangya Hospital of Central South UniversityRan2014 to 2017Enrolled660ConditionsAtrial Fibrillation, Deep Venous ThrombosisArmsGenotype-guided dosing algorithm for warfarin, Standard initiation dose for warfarin
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Ethnic Diversity and Warfarin Pharmacogenomics.Frontiers in pharmacology · 2022
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

54 authors at 15 institutions in 2 countries.

Chengxian Guo *Center of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Yun Kuang *Center of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital (H.Z., Xiaoping Chen), Central South University, Changsha, China.
Hong YuanCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Qi PeiDepartment of Pharmacy (C.G., Q.P., L.H., Jinfu Peng, G.Y.), Central South University, Changsha, China.
Jingle LiDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Weihong JiangDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Chee M NgCollege of Pharmacy, University of Kentucky, Lexington (C.M.N.).
Xiaoping ChenDepartment of Clinical Pharmacology, Xiangya Hospital (H.Z., Xiaoping Chen), Central South University, Changsha, China.
Yong HuoDepartment of Cardiology (Y.H.), Peking University Health Science Center, Beijing, China.
Yimin CuiDepartment of Pharmacy, Peking University First Hospital (Y.C.), Peking University Health Science Center, Beijing, China.
Xiaobin WangDepartment of Population, Family and Reproductive Health, Center on the Early Life Origins of Disease, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (Xiaobin Wang).
Jingjing YuCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Xue SunCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Wanying YuCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Peng ChenCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Da MiaoCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Wenyu LiuCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Zaixin YuDepartment of Cardiology, Third Hospital of Changsha, China (Y.Z.).
Zewei OuyangDepartment of Cardiology, Shaoyang Central Hospital, China (Z.O., X. Shi).
Xiangjiang ShiDepartment of Cardiology, Shaoyang Central Hospital, China (Z.O., X. Shi).
Chunmei LvDepartment of Cardiology, The First People's Hospital of Shaoyang, China (C.L., Z.P.).
Zijing PengDepartment of Cardiology, The First People's Hospital of Shaoyang, China (C.L., Z.P.).
Guozuo XiongDepartment of Vascular Surgery (G.X.), The Second Affiliated Hospital, University of South China, Hengyang.
Gaofeng ZengDepartment of Cardiology (G.Z.), The Second Affiliated Hospital, University of South China, Hengyang.
Jianping ZengDepartment of Cardiology, Xiangtan Central Hospital, China (J.Z.).
Haiying DaiDepartment of Cardiology, Changsha Central Hospital, China (H.D.).
Jianqiang PengDepartment of Cardiology, Hunan Provincial People's Hospital, China (Jianqiang Peng).
Yuming ZhangDepartment of Cardiology, Third Hospital of Changsha, China (Y.Z.).
Fanghua XuDepartment of Cardiology, First People's Hospital of Xiangtan City, China (F.X.).
Jie WuDepartment of Cardiology, First Affiliated Hospital of University of South China, Hengyang (J.W.).
Xiaoliang ChenDepartment of Cardiology, Chenzhou First People's Hospital, China (Xiaoliang Chen).
Hao GongDepartment of Cardiology, The Fourth Hospital of Changsha, China (H.G.).
Zhiyuan YangDepartment of Cardiology, Loudi Central Hospital, China (Z. Yang).
Xianming WuDepartment of Cardiology, Yiyang Central Hospital, China (X. Wu).
Qiulian FangSchool of Mathematics and Statistics (Q.F., L.Y.), Central South University, Changsha, China.
Liu YangSchool of Mathematics and Statistics (Q.F., L.Y.), Central South University, Changsha, China.
Haigang LiDepartment of Pharmacy, Changsha Medical University, China (H.L.).
Hongyi TanCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Zhijun HuangCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Xiaohong TangDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Qiong YangDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Shan TuDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Xiaoyan WangDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Yuxia XiangCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Jie HuangCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Xiaomin WangCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Jingjing CaiDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Shanjie JiangDepartment of Cardiology, The Third Xiangya Hospital (J.L., W.J., X.T., Q.Y., S.T., Xiaoyan Wang, J.C., S.J.), Central South University, Changsha, China.
Lu HuangDepartment of Pharmacy (C.G., Q.P., L.H., Jinfu Peng, G.Y.), Central South University, Changsha, China.
Jinfu PengDepartment of Pharmacy (C.G., Q.P., L.H., Jinfu Peng, G.Y.), Central South University, Changsha, China.
Liying GongCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Chan ZouCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Guoping YangCenter of Clinical Pharmacology, the Third Xiangya Hospital (C.G., Y.K., H.Y., J.Y., X. Sun, W.Y., P.C., D.M., W.L., H.T., Z.H., Y.X., J.H., Xiaomin Wang, L.G., C.Z., G.Y.), Central South University, Changsha, China.
Central South University · CNThe Central Hospital of Shaoyang · CNPeking University · CNUniversity of South China · CNChangsha Central Hospital · CNChangsha Medical University · CNFirst Affiliated Hospital of University of South China · CNFourth Hospital of Changsha · CNLoudi Central Hospital · CNThird Hospital of Changsha · CNUniversity of Kentucky · USXiangyang Central Hospital · CNXian Yang Central Hospital · CNXuzhou Medical College · CNYixing Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWarfarin is an effective treatment for thromboembolic disease but has a narrow therapeutic index; optimal anticoagulation dosage can differ tremendously among individuals. We aimed to evaluate whether genotype-guided warfarin dosing is superior to routine clinical dosing for the outcomes of interest in Chinese patients.

methodsWe conducted a multicenter, randomized, single-blind, parallel-controlled trial from September 2014 to April 2017 in 15 hospitals in China. Eligible patients were ≥18 years of age, with atrial fibrillation or deep vein thrombosis without previous treatment of warfarin or a bleeding disorder. Nine follow-up visits were performed during the 12-week study period. The primary outcome measure was the percentage of time in the therapeutic range of the international normalized ratio during the first 12 weeks after starting warfarin therapy.

resultsA total of 660 participants were enrolled and randomly assigned to a genotype-guided dosing group or a control group under standard dosing. The genotype-guided dosing group had a significantly higher percentage of time in the therapeutic range than the control group (58.8% versus 53.2% [95% CI of group difference, 1.1-10.2];

conclusionsThe outcomes of genotype-guided warfarin dosing were superior to those of clinical standard dosing. These findings raise the prospect of precision warfarin treatment in China. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02211326.

Indexed as

AgedAnticoagulantsAsian PeopleAtrial FibrillationChinaCytochrome P-450 CYP2C9Dose-Response Relationship, DrugDrug Administration ScheduleFemaleGenotypeHemorrhageHumansInternational Normalized RatioMaleMiddle AgedSingle-Blind MethodAnticoagulantsCYP2C9 protein, humanCytochrome P-450 CYP2C9Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarinatrial fibrillationcontrol groupspharmacogeneticsrandomized controlled trialwarfarin

Identifiers

PMID32510984
PMCPMC7439928
OpenAlexW3033437687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.